Keywords
How to Cite
Abstract
Introduction: Vancomycin is a glycopeptide antibiotic widely used in the treatment of serious infections caused by Gram-positive microorganisms, including resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA). However, its prolonged use or at inadequate doses is associated with a series of adverse effects, with acute kidney injury (AKI) being one of the most worrying complications. Objective: To analyze the use of vancomycin and piperacillin-tazobactam combination therapy in acute kidney injury. Methodology: This is a literature review that included clinical trials in English and Portuguese, published between 2016 and 2024, selected from the PubMed, Scopus and SciELO databases. After careful selection, 8 articles were chosen to compose this literature review. Results: The combination of vancomycin with piperacillin-tazobactam (TZP) is associated with an increased risk of acute kidney injury (AKI) in critically ill pediatric and adult patients, especially when compared with other antibiotic combinations. Considerations: The combination of vancomycin with TZP is associated with an increased risk of acute kidney injury. It is crucial to closely monitor renal function during therapy with this combination and to consider alternatives with a lower risk of AKI, such as vancomycin with meropenem or ceftriaxone.
References
ABOUELKHEIR, M.; ALSUBAIE, S. Pediatric acute kidney injury induced by concomitant vancomycin and piperacillin-tazobactam. Pediatrics International, v. 60, n. 2, p. 136–141, fev. 2018.
AL YAMI, M. S. Comparison of the incidence of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or with meropenem. Journal of Infection and Public Health, v. 10, n. 6, p. 770–773, nov.-dez. 2017.
AWDISHU, L. et al. Urinary exosomes identify inflammatory pathways in vancomycin associated acute kidney injury. International Journal of Molecular Sciences, v. 22, p. 2784, 2021.
BUHLINGER, K. M. et al. Effect of concomitant vancomycin and piperacillin-tazobactam on frequency of acute kidney injury in pediatric patients. American Journal of Health-System Pharmacy, v. 76, n. 16, p. 1204–1210, 1 ago. 2019.
DOWNES, K. J. et al. Association of acute kidney injury with concomitant vancomycin and piperacillin/tazobactam treatment among hospitalized children. JAMA Pediatrics, v. 171, n. 12, p. e173219, 4 dez. 2017.
DRUML, W. Systemic consequences of acute kidney injury. Current Opinion in Critical Care, v. 20, p. 613–619, 2014.
HOLSEN, M. R. et al. Increased risk of acute kidney injury in critically ill children treated with vancomycin and piperacillin/tazobactam. Pediatric Critical Care Medicine, v. 18, n. 12, p. e585–e591, dez. 2017.
HOSTE, E. A. et al. Epidemiology of acute kidney injury in critically ill patients: The multinational AKI-EPI study. Intensive Care Medicine, v. 41, p. 1411–1423, 2015.
JORGENSEN, S. C. J. et al. A multicenter evaluation of vancomycin-associated acute kidney injury in hospitalized patients with acute bacterial skin and skin structure infections. Infectious Diseases and Therapy, v. 9, p. 89–106, 2020.
KANG, S. et al. Comparison of acute kidney injury and clinical prognosis of vancomycin monotherapy and combination therapy with beta-lactams in the intensive care unit. PLoS One, v. 14, n. 6, p. e0217908, 5 jun. 2019.
KUNMING, P. et al. Vancomycin associated acute kidney injury: A longitudinal study in China. Frontiers in Pharmacology, v. 12, p. 632107, 2021.
MCQUEEN, K. E.; CLARK, D. W. Does combination therapy with vancomycin and piperacillin-tazobactam increase the risk of nephrotoxicity versus vancomycin alone in pediatric patients? Journal of Pediatric Pharmacology and Therapeutics, v. 21, n. 4, p. 332–338, jul.-ago. 2016.
MITEVSKA, E. et al. The prevalence, risk, and management of methicillin-resistant Staphylococcus aureus infection in diverse populations across Canada: A systematic review. Pathogens, v. 10, p. 393, 2021.
PETEJOVA N., Martinek A., Zadrazil J., Kanova M., Klementa V., Sigutova R., Kacirova I., Hrabovsky V., Svagera Z., Stejskal D. Acute kidney injury in septic patients treated by selected nephrotoxic antibiotic agents-pathophysiology and biomarkers-a review. Int. J. Mol. Sci. 2020;21:7115.
PETEJOVA, N. et al. Acute kidney injury in septic patients treated by selected nephrotoxic antibiotic agents-pathophysiology and biomarkers-a review. International Journal of Molecular Sciences, v. 21, p. 7115, 2020.
ROBERTSON, A. D. et al. Incidence of acute kidney injury among patients receiving the combination of vancomycin with piperacillin-tazobactam or meropenem. Pharmacotherapy, v. 38, n. 12, p. 1184–1193, dez. 2018.
TANTRANONT, N. et al. Vancomycin nephrotoxicity: Vancomycin tubular casts with characteristic electron microscopic findings. Clinical Nephrology Case Studies, v. 7, p. 66–72, 2019.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2024 Júlia Leandra Fernandes , Mateus Pozza, José Henrique Beserra, Carolina Leite de Oliveira, Victor Hugo Mundim Melo, Maria Luiza Bertozi Francisco, Alex Italo da Silveira Sales, Gabrielly Alves Trigo, Rodrigo Cordon Isaac, André Breda Bauab Filho, Sabrina Furtunato de Oliveira, Maria Eduarda Almeida Cavalcanti, Tarcísio Fernando Honorio da Silva, Allycia Jamylle Nogueira de Mello, Paula Rafaela Nunes do Carmo, Lucas dos Santos Silva, Lucélia Barros Tenório, Bruna Michelly de Barros Canuto Pinheiro, Lara Amaral Santos Cunha
